Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$0.00
$0.00
$0.00
$2.87
$1K3516.091,770 shs1,509 shs
Immatics N.V. stock logo
IMTX
Immatics
$5.54
+3.0%
$5.25
$3.30
$13.09
$673.39M0.83675,904 shs436,226 shs
Therapeutics Acquisition Corp. stock logo
RACA
Therapeutics Acquisition
$9.53
$9.81
$21.44
$175.51MN/A105,531 shsN/A
THCA
Tuscan Holdings Corp. II
$10.47
$10.46
$10.18
$13.77
$77.02M0.11117,672 shs310 shs
Spartacus Acquisition Co. stock logo
TMTS
Spartacus Acquisition
$10.86
$10.48
$9.65
$11.03
$217.20MN/A95,063 shs78,933 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
0.00%0.00%0.00%+100.00%-99.98%
Immatics N.V. stock logo
IMTX
Immatics
-0.92%-0.74%-3.41%+34.50%-53.70%
Therapeutics Acquisition Corp. stock logo
RACA
Therapeutics Acquisition
0.00%0.00%0.00%0.00%0.00%
THCA
Tuscan Holdings Corp. II
0.00%0.00%0.00%0.00%0.00%
Spartacus Acquisition Co. stock logo
TMTS
Spartacus Acquisition
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
N/AN/AN/AN/AN/AN/AN/AN/A
Immatics N.V. stock logo
IMTX
Immatics
3.0698 of 5 stars
3.64.00.00.03.51.70.0
Therapeutics Acquisition Corp. stock logo
RACA
Therapeutics Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
THCA
Tuscan Holdings Corp. II
N/AN/AN/AN/AN/AN/AN/AN/A
Spartacus Acquisition Co. stock logo
TMTS
Spartacus Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
0.00
N/AN/AN/A
Immatics N.V. stock logo
IMTX
Immatics
3.20
Buy$14.67164.74% Upside
Therapeutics Acquisition Corp. stock logo
RACA
Therapeutics Acquisition
0.00
N/AN/AN/A
THCA
Tuscan Holdings Corp. II
0.00
N/AN/AN/A
Spartacus Acquisition Co. stock logo
TMTS
Spartacus Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CLVR, TMTS, RACA, THCA, and IMTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Immatics N.V. stock logo
IMTX
Immatics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
4/1/2025
Immatics N.V. stock logo
IMTX
Immatics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$17.42M0.00N/AN/A$14.02 per share0.00
Immatics N.V. stock logo
IMTX
Immatics
$168.65M3.99$0.25 per share22.22$5.12 per share1.08
Therapeutics Acquisition Corp. stock logo
RACA
Therapeutics Acquisition
N/AN/AN/AN/AN/AN/A
THCA
Tuscan Holdings Corp. II
N/AN/A$0.37 per share27.93($0.67) per shareN/A
Spartacus Acquisition Co. stock logo
TMTS
Spartacus Acquisition
N/AN/AN/AN/A$0.25 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
-$17.90M-$11.31N/AN/AN/AN/AN/AN/A
Immatics N.V. stock logo
IMTX
Immatics
$16.47M-$0.17N/AN/AN/A-14.73%-4.52%-3.34%8/12/2025 (Estimated)
Therapeutics Acquisition Corp. stock logo
RACA
Therapeutics Acquisition
N/AN/A0.00N/AN/AN/AN/AN/AN/A
THCA
Tuscan Holdings Corp. II
$1.78MN/A0.00N/AN/A-6.82%0.33%N/A
Spartacus Acquisition Co. stock logo
TMTS
Spartacus Acquisition
-$3.73MN/A0.00N/AN/AN/AN/AN/A

Latest CLVR, TMTS, RACA, THCA, and IMTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Immatics N.V. stock logo
IMTX
Immatics
-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
N/AN/AN/AN/AN/A
Immatics N.V. stock logo
IMTX
Immatics
N/AN/AN/AN/AN/A
Therapeutics Acquisition Corp. stock logo
RACA
Therapeutics Acquisition
N/AN/AN/AN/AN/A
THCA
Tuscan Holdings Corp. II
N/AN/AN/AN/AN/A
Spartacus Acquisition Co. stock logo
TMTS
Spartacus Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
N/AN/AN/A
Immatics N.V. stock logo
IMTX
Immatics
N/A
10.28
10.28
Therapeutics Acquisition Corp. stock logo
RACA
Therapeutics Acquisition
N/A
0.13
0.13
THCA
Tuscan Holdings Corp. II
N/A
0.06
0.06
Spartacus Acquisition Co. stock logo
TMTS
Spartacus Acquisition
0.06
0.30
0.30
CompanyEmployeesShares OutstandingFree FloatOptionable
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
5601.76 million1.61 millionNo Data
Immatics N.V. stock logo
IMTX
Immatics
260121.55 millionN/AOptionable
Therapeutics Acquisition Corp. stock logo
RACA
Therapeutics Acquisition
N/A14.04 millionN/ANot Optionable
THCA
Tuscan Holdings Corp. II
N/A7.36 million2.87 millionNot Optionable
Spartacus Acquisition Co. stock logo
TMTS
Spartacus Acquisition
220.00 millionN/ANot Optionable

Recent News About These Companies

Spartacus (1960)
Majestic Gold flags potential China acquisition
Gary Lineker the Spartacus of the social media age
NextNav Announces Date for Third Quarter 2021 Earnings Call
Tag: TMTS stock
Spartacus Acquisition Corp. Cl A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Clever Leaves stock logo

Clever Leaves NASDAQ:CLVR

$0.0004 0.00 (0.00%)
As of 06/30/2025 12:27 PM Eastern

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

Immatics stock logo

Immatics NASDAQ:IMTX

$5.54 +0.16 (+2.97%)
Closing price 04:00 PM Eastern
Extended Trading
$5.54 0.00 (-0.09%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Therapeutics Acquisition stock logo

Therapeutics Acquisition NASDAQ:RACA

Therapeutics Acquisition Corp., doing business as Research Alliance Corp. I, does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was incorporated in 2020 and is based in Boston, Massachusetts.

Tuscan Holdings Corp. II NASDAQ:THCA

Tuscan Holdings Corp. II does not have significant operations. It intends to merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities in the cannabis industry. The company was incorporated in 2019 and is based in New York, New York. Tuscan Holdings Corp. II operates as a subsidiary of Tuscan Holdings Acquisition II LLC.

Spartacus Acquisition stock logo

Spartacus Acquisition NASDAQ:TMTS

Spartacus Acquisition Corporation does not have significant operations. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Duluth, Georgia.